TNB Financial Sells 45 Shares of C.R. Bard, Inc. (NYSE:BCR)

TNB Financial lowered its position in C.R. Bard, Inc. (NYSE:BCR) by 1.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,100 shares of the medical instruments supplier’s stock after selling 45 shares during the period. TNB Financial’s holdings in C.R. Bard were worth $980,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. SRS Capital Advisors Inc. increased its stake in C.R. Bard by 0.7% in the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock worth $148,000 after buying an additional 4 shares in the last quarter. Burns J W & Co. Inc. NY boosted its position in shares of C.R. Bard by 1.3% in the first quarter. Burns J W & Co. Inc. NY now owns 1,581 shares of the medical instruments supplier’s stock worth $393,000 after buying an additional 21 shares during the last quarter. Creative Planning boosted its position in shares of C.R. Bard by 0.7% in the first quarter. Creative Planning now owns 4,298 shares of the medical instruments supplier’s stock worth $1,068,000 after buying an additional 29 shares during the last quarter. Blair William & Co. IL boosted its position in shares of C.R. Bard by 0.9% in the first quarter. Blair William & Co. IL now owns 3,492 shares of the medical instruments supplier’s stock worth $865,000 after buying an additional 30 shares during the last quarter. Finally, Pennsylvania Trust Co boosted its position in shares of C.R. Bard by 2.9% in the first quarter. Pennsylvania Trust Co now owns 1,240 shares of the medical instruments supplier’s stock worth $308,000 after buying an additional 35 shares during the last quarter. 87.63% of the stock is owned by institutional investors.

Shares of C.R. Bard, Inc. (BCR) traded down 0.12% during trading on Monday, hitting $319.65. 170,760 shares of the company traded hands. The company has a market capitalization of $23.15 billion, a price-to-earnings ratio of 40.68 and a beta of 0.59. The company has a 50 day moving average price of $311.80 and a 200 day moving average price of $264.06. C.R. Bard, Inc. has a 52 week low of $203.63 and a 52 week high of $320.37.

C.R. Bard (NYSE:BCR) last posted its quarterly earnings results on Sunday, April 23rd. The medical instruments supplier reported $2.87 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.65 by $0.22. The company had revenue of $938.80 million for the quarter, compared to the consensus estimate of $916.15 million. C.R. Bard had a net margin of 15.70% and a return on equity of 48.72%. The firm’s revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the firm posted $2.34 EPS. On average, analysts expect that C.R. Bard, Inc. will post $11.78 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, August 4th. Investors of record on Monday, July 24th will be paid a $0.26 dividend. This represents a $1.04 annualized dividend and a yield of 0.33%. The ex-dividend date of this dividend is Thursday, July 20th. C.R. Bard’s dividend payout ratio is presently 13.21%.

WARNING: “TNB Financial Sells 45 Shares of C.R. Bard, Inc. (NYSE:BCR)” was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.com-unik.info/2017/07/17/tnb-financial-sells-45-shares-of-c-r-bard-inc-nysebcr.html.

A number of equities analysts recently commented on the stock. Zacks Investment Research cut shares of C.R. Bard from a “buy” rating to a “hold” rating in a research report on Monday. BMO Capital Markets reiterated a “hold” rating and issued a $317.00 target price on shares of C.R. Bard in a research report on Tuesday, July 11th. BidaskClub upgraded shares of C.R. Bard from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 8th. Raymond James Financial, Inc. cut shares of C.R. Bard from a “strong-buy” rating to a “mkt perform” rating in a research report on Wednesday, April 26th. Finally, Wells Fargo & Company cut shares of C.R. Bard from an “outperform” rating to a “market perform” rating in a research report on Tuesday, April 25th. Eleven analysts have rated the stock with a hold rating, two have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $271.31.

In related news, VP Frank Lupisella, Jr. sold 3,622 shares of the firm’s stock in a transaction dated Monday, April 24th. The shares were sold at an average price of $304.00, for a total value of $1,101,088.00. Following the transaction, the vice president now owns 10,139 shares of the company’s stock, valued at approximately $3,082,256. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.80% of the company’s stock.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

What are top analysts saying about C.R. Bard Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for C.R. Bard Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit